摘要
目的探讨血清S100B在急性颅脑损伤预后评估的临床应用价值。方法以电化学发光免疫法检测77例急性颅脑损伤患者伤后3h内的血清S100B含量,以扩展Glasgow结果评分评价其伤后6个月的康复情况,并对两者的关系进行受试者操作特性分析。结果血清S100B含量低于0·42μg/L者预后良好,其敏感度为78·8%,特异度为88·9%。结论血清S100B可以用作评估急性颅脑损伤预后的神经化学标志物。
Objective To investigate the clinical significance of serum S100B in prediction of prognosis of acute craniocerebral injury. Methods The concentration of serum S100B in 77 patients was determined within 3 hours after craniocerebral injury by electrochemil immunoassay while their outcomes were assessed at 6 months with the extended Glasgow outcome scale. The relationship between them was evaluated using the receiver operating characteristic analysis. Results The patients with less than 0.42 μg/L recovered very well. The sensitivity of the serum S100B was 78. 8% with the specificity 88.9%. Conclusion Serum S100B can be a clinically practical neurochemical marker to predict prognosis of acute craniocerebral injury.
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2006年第4期328-330,共3页
Chinese Journal of Laboratory Medicine
